Inclusion Criteria:

- Histological or cytological proof of advanced C-KIT positive or PDGFR positive thymic
carcinoma. For protocol purposes, advanced disease is defined as disease

- Patient must have at least one documented measurable lesion obtained by imaging
within 28 days prior to being registered for protocol therapy.

- No prior imatinib therapy.

- Age > 18 years at the time of consent

- ECOG performance status of 0 or 1

- ANC ≥ 1500/mm3,Platelet count ≥ 100,000/mm,Total bilirubin < 1.5ULN,3.10 Serum
creatinine ≤ 1.7 mg/dl,ALT and AST ≤ 3 x ULN

Exclusion Criteria:

- Clinically significant infections as judged by the treating investigator

- Clinically significant concurrent illnesses

- Females of childbearing potential not using birth control or breastfeeding

- Prior radiation therapy > 25% of the bone marrow

- Symptomatic brain metastasis

- History of Grade III/IV cardiac problems

- History of major surgery within 14 days prior to being registered

- Treatment with any investigational agent within 30 days prior to being registered for
protocol therapy.